Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Oramed Pharmaceuticals Inc.

Regulatory Filings • Jan 6, 2026

6965_rns_2026-01-06_e2cdbc22-076d-4ac0-8eeb-496db2707550.pdf

Regulatory Filings

Open in Viewer

Opens in native device viewer

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHAN GES IN

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a
transaction was made pursuant to a
contract, instruction or written plan for
the purchase or sale of equity
securities of the issuer that is intended
to satisfy the affirmative defense
conditions of Rule 10b5-1(c). See
Instruction 10.
Gabay Avraham 1. Name and Address of Reporting Person* 2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director		 10% Owner
ORMP ] below) Officer (give title Other (specify
below)
(Last)
THIRD FLOOR		 (First) 1185 AVENUE OF THE AMERICAS, (Middle) 3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025		 Chief Financial Officer
(Street)
NEW YORK		 NY 10036 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable
Line)
Form filed by One Reporting Person
Form filed by More than One Reporting
Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction
2A. Deemed
Date
(Month/Day/Year)
if any		 Execution Date,
(Month/Day/Year)		 3.
4. Securities Acquired (A) or
Transaction
Disposed Of (D) (Instr. 3, 4 and 5)
Code (Instr.
8)		 5. Amount of
Securities
Beneficially
Owned Following
Reported		 6. Ownership
Form: Direct
(D) or Indirect
(I) (Instr. 4)		 7. Nature of
Indirect
Beneficial
Ownership
(Instr. 4)
Code V Amount (A) or
(D)		 Price Transaction(s)
(Instr. 3 and 4)
Common Stock 12/31/2025 A 81,216(1) A \$0
(1)		 515,256 D
Common Stock 12/31/2025 A 115,000(2) A \$0
(2)		 630,256 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of
Derivative
Security
(Instr. 3)		 2.
Conversion
or Exercise
Price of
Derivative
Security		 3. Transaction
Date
(Month/Day/Year)		 3A. Deemed
Execution Date,
if any
(Month/Day/Year)		 4.
8)		 5. Number
Transaction
of
Code (Instr.
Derivative
Securities
Acquired
(A) or
Disposed
of (D) (Instr.
3, 4 and 5)		 6. Date Exercisable and
7. Title and Amount
Expiration Date
of Securities
(Month/Day/Year)
Underlying
Derivative Security
(Instr. 3 and 4)		 8. Price of
Derivative
Security
(Instr. 5)		 9. Number of
derivative
Securities
Beneficially
Owned
Following
Reported
Transaction(s)
(Instr. 4)		 10.
Ownership
Form:
Direct (D)
or Indirect
(I) (Instr. 4)		 11. Nature
of Indirect
Beneficial
Ownership
(Instr. 4)
Code V (A) (D) Date
Exercisable		 Expiration
Date		 Title Amount
or
Number
of
Shares
Performance
Stock Units		 (3) 12/31/2025 A 19,000 (3) (3) Common
Stock		 19,000 \$0 19,000 D

Explanation of Responses:

    1. Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value \$0.012 per share ("Common Stock"), of the Issuer.
    1. Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.
    1. Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria.

/s/ Avraham Gabay 01/02/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

  • * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
  • ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Instruction 1(b).

intended to satisfy the affirmative defense conditions of Rule 10b5-

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_ _ - _ - _ - •
٧a ash nino ote n. D. C. 20 054 19
Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is

1(c). See Instruction 10.
Aghion Daniel 1. Name and Address of Reporting Person* 2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ (Check all applicable) 5. Relationship of Reporting Person(s) to Issuer
ORMP ] Director 10% Owner
(Last) (First) (Middle) below) Officer (give title Other (specify
below)
1185 AVENUE OF THE AMERICAS 3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable
(Street) Line)
NEW YORK NY 10036 Form filed by One Reporting Person
(City) (State) (Zip) Person Form filed by More than One Reporting
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)
2. Transaction
Date
(Month/Day/Year)		 2A. Deemed
Execution Date,
if any
(Month/Day/Year)		 3.
Transaction
Code (Instr.
8)		 4. Securities Acquired (A) or
Disposed Of (D) (Instr. 3, 4 and
5)		 5. Amount of
Securities
Beneficially
Owned Following
Reported		 6. Ownership
Form: Direct
(D) or Indirect
(I) (Instr. 4)		 7. Nature
of Indirect
Beneficial
Ownership
Code V Amount (D) (A) or Price Transaction(s)
(Instr. 3 and 4)		 (Instr. 4)
Common Stock 12/31/2025 A 30,000(1) A (1) 107,191 D
Common Stock 12/31/2025 A 6,250(2) A (2) 113,441 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of
Derivative
Security
(Instr. 3)		 2.
Conversion
or Exercise
Price of
Derivative
Security		 3. Transaction
Date
(Month/Day/Year)		 3A. Deemed
if any		 Execution Date,
(Month/Day/Year)		 4.
8)		 5. Number
Transaction
of
Code (Instr.
Derivative
Securities
Acquired
(A) or
Disposed
of (D)
(Instr. 3, 4
and 5)		 6. Date Exercisable and
Expiration Date
(Month/Day/Year)		 3 and 4) 7. Title and
Amount of
Securities
Underlying
Derivative
Security (Instr.		 Security
(Instr. 5)		 8. Price of
9. Number of
Derivative
derivative
Securities
Beneficially
Owned
Following
Reported
Transaction(s)
(Instr. 4)		 10.
Ownership
Form:
Direct (D)
or Indirect
(I) (Instr. 4)		 11. Nature
of Indirect
Beneficial
Ownership
(Instr. 4)
Code V (A) (D) Date
Exercisable		 Expiration
Date		 Title Amount
or
Number
of
Shares

Explanation of Responses:

    1. Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value \$0.012 per share ("Common Stock"), of the Issuer.
    1. Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.

/s/ Daniel Aghion 01/02/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

  • * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
  • ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response:
0.5
Check this box to indicate that a
transaction was made pursuant to a
contract, instruction or written plan
for the purchase or sale of equity
securities of the issuer that is
intended to satisfy the affirmative
defense conditions of Rule 10b5-

Instruction 1(b).

Reznick Yehuda 1. Name and Address of Reporting Person* 2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director
10% Owner
(Last) (First) (Middle) ORMP ] below) Officer (give title Other (specify
below)
THIRD FLOOR 1185 AVENUE OF THE AMERICAS, 12/31/2025 3. Date of Earliest Transaction (Month/Day/Year)
(Street)
NEW YORK		 NY 10036 4. If Amendment, Date of Original Filed (Month/Day/Year) Line) 6. Individual or Joint/Group Filing (Check Applicable
Form filed by One Reporting Person
(City) (State) (Zip) Person Form filed by More than One Reporting
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction
Date
(Month/Day/Year)		 if any 2A. Deemed
Execution Date,
(Month/Day/Year)		 3.
Transaction
Code (Instr.
8)		 4. Securities Acquired (A) or
Disposed Of (D) (Instr. 3, 4 and
5)		 5. Amount of
Securities
Beneficially		 Owned Following (I) (Instr. 4) 6. Ownership
Form: Direct
(D) or Indirect		 7. Nature
of Indirect
Beneficial
Ownership
Code V Amount (D) (A) or Price Reported Transaction(s)
(Instr. 3 and 4)		 (Instr. 4)
Common Stock 12/31/2025 A 30,000(1) A (1) 98,930 D
Common Stock 12/31/2025 A 6,250(2) A (2) 105,180 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of
Derivative
Security
(Instr. 3)		 2.
Conversion
or Exercise
Price of
Derivative
Security		 3. Transaction
Date
(Month/Day/Year)		 3A. Deemed
if any		 Execution Date,
(Month/Day/Year)		 4.
8)		 5. Number
Transaction
of
Code (Instr.
Derivative
Securities
Acquired
(A) or
Disposed
of (D)
(Instr. 3, 4
and 5)		 Expiration Date
(Month/Day/Year)		 6. Date Exercisable and 7. Title and
Amount of
Securities
Underlying
Derivative
3 and 4)		 Security (Instr. 8. Price of
Derivative
Security
(Instr. 5)		 9. Number of
derivative
Securities
Beneficially
Owned
Following
Reported
Transaction(s)
(Instr. 4)		 10.
Ownership
Form:
Direct (D)
or Indirect
(I) (Instr. 4)		 11. Nature
of Indirect
Beneficial
Ownership
(Instr. 4)
Date Expiration Amount
or
Number
of

Explanation of Responses:

    1. Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value \$0.012 per share ("Common Stock"), of the Issuer.
    1. Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.

/s/ Yehuda Reznick 01/05/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

  • * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
  • ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
Vashington. D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response:
0.5
Check this box to indicate that a
transaction was made pursuant to a
contract, instruction or written plan
for the purchase or sale of equity
securities of the issuer that is
intended to satisfy the affirmative
defense conditions of Rule 10b5-

Instruction 1(b).

Mayer Arie 1. Name and Address of Reporting Person* ORMP ] 2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ (Check all applicable)
Director		 5. Relationship of Reporting Person(s) to Issuer 10% Owner
(Last) 16 MORAN STREET (First) (Middle) 12/31/2025 3. Date of Earliest Transaction (Month/Day/Year) below) Officer (give title Other (specify
below)
(Street)
KFAR SABA
(City)		 L3 (State) 4428890
(Zip)		 4. If Amendment, Date of Original Filed (Month/Day/Year) Line) Person 6. Individual or Joint/Group Filing (Check Applicable
Form filed by One Reporting Person
Form filed by More than One Reporting
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)
Date		 2. Transaction
(Month/Day/Year)		 2A. Deemed
Execution Date,
if any
(Month/Day/Year)		 3.
Transaction
Code (Instr.
8)		 4. Securities Acquired (A) or
Disposed Of (D) (Instr. 3, 4 and
5)		 5. Amount of
Securities
Beneficially
Reported		 Owned Following 6. Ownership
Form: Direct
(D) or Indirect
(I) (Instr. 4)		 7. Nature
of Indirect
Beneficial
Ownership
(Instr. 4)
Code V Amount (D) (A) or Price Transaction(s)
(Instr. 3 and 4)
Common Stock 12/31/2025 A 30,000(1) A (1) 163,109 D
Common Stock 12/31/2025 A 4,900(2) A (2) 168,009 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of
Derivative
Security
(Instr. 3)		 2.
3. Transaction
3A. Deemed
4.
Conversion
Date
Execution Date,
Transaction
of
or Exercise
(Month/Day/Year)
if any
Code (Instr.
Price of
(Month/Day/Year)
8)
Derivative
Security		 5. Number
6. Date Exercisable and
7. Title and
Expiration Date
Amount of
Derivative
(Month/Day/Year)
Securities
Securities
Underlying
Acquired
Derivative
(A) or
Security (Instr.
Disposed
3 and 4)
of (D)
(Instr. 3, 4
and 5)		 8. Price of
Derivative
Security
(Instr. 5)		 9. Number of
derivative
Securities
Beneficially
Owned
Following
Reported
Transaction(s)
(Instr. 4)		 10.
Ownership
Form:
Direct (D)
or Indirect
(I) (Instr. 4)		 11. Nature
of Indirect
Beneficial
Ownership
(Instr. 4)
Amount
or
Number
Date
Expiration
of

Explanation of Responses:

  1. Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value \$0.012 per share ("Common Stock"), of the Issuer.

Exercisable

  1. Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.

Code V (A) (D)

Date Title

/s/ Arie Mayer 01/05/2026

** Signature of Reporting Person Date

Shares

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

  • * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
  • ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box to indicate that a
transaction was made pursuant to a
contract, instruction or written plan for
the purchase or sale of equity
securities of the issuer that is intended
to satisfy the affirmative defense
conditions of Rule 10b5-1(c). See
Instruction 10.
1. Name and Address of Reporting Person* 2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Kidron Miriam ORMP ] Director 10% Owner
(Last) (First) (Middle) below) Officer (give title Other (specify
below)
FLOOR 1185 AVENUE OF THE AMERICAS, THIRD 12/31/2025 3. Date of Earliest Transaction (Month/Day/Year) Chief Scientific Officer
4. If Amendment, Date of Original Filed (Month/Day/Year) Line) 6. Individual or Joint/Group Filing (Check Applicable
(Street)
NEW YORK		 NY 10036 Form filed by One Reporting Person
Person Form filed by More than One Reporting
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)
2. Transaction
Date
(Month/Day/Year)		 2A. Deemed
Execution Date,
if any
(Month/Day/Year)		 3.
Transaction
Code (Instr.
8)		 4. Securities Acquired (A) or
Disposed Of (D) (Instr. 3, 4 and 5)		 5. Amount of
Securities
Beneficially
Owned Following
Reported		 6. Ownership
Form: Direct
(D) or Indirect
(I) (Instr. 4)		 7. Nature of
Indirect
Beneficial
Ownership
(Instr. 4)
Code V Amount (A) or
(D)		 Price Transaction(s)
(Instr. 3 and 4)
Common Stock 12/31/2025 A 121,331(1) A \$0
(1)		 1,314,664 D
Common Stock 12/31/2025 A 115,000(2) A \$0
(2)		 1,429,664 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of
Derivative
Security
(Instr. 3)		 2.
Conversion
or Exercise
Price of
Derivative
Security		 3. Transaction
Date
(Month/Day/Year)		 3A. Deemed
Execution Date,
if any
(Month/Day/Year)		 4.
8)		 5. Number
Transaction
of
Code (Instr.
Derivative
Securities
Acquired
(A) or
Disposed
of (D) (Instr.
3, 4 and 5)		 6. Date Exercisable and
Expiration Date
(Month/Day/Year)		 7. Title and Amount
of Securities
Underlying
Derivative Security
(Instr. 3 and 4)		 Amount 8. Price of
Derivative
Security
(Instr. 5)		 9. Number of
derivative
Securities
Beneficially
Owned
Following
Reported
Transaction(s)
(Instr. 4)		 10.
Ownership
Form:
Direct (D)
or Indirect
(I) (Instr. 4)		 11. Nature
of Indirect
Beneficial
Ownership
(Instr. 4)
Code V
(A)
(D)		 Exercisable Expiration
Date
Title		 or
Number
of
Shares

Explanation of Responses:

Performance Stock Units

    1. Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value \$0.012 per share ("Common Stock"), of the Issuer.
    1. Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.

(3) 12/31/2025 A 19,000 (3) (3) Common

  1. Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria.

/s/ Miriam Kidron 01/05/2026

** Signature of Reporting Person Date

Stock 19,000 \$0 19,000 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

  • * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
  • ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
-- -- -- -- -- ----------------------------------------------

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

to satisfy the affirmative defense
conditions of Rule 10b5-1(c). See
Instruction 10.
1. Name and Address of Reporting Person*
Hexter Joshua
(Last)
FLOOR		 (First)
1185 AVENUE OF THE AMERICAS, THIRD		 2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [
ORMP ]
3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025		 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director
10% Owner
Officer (give title
Other (specify
below)
below)
COO & CBO
(Street)
NEW YORK
(City)		 NY
(State)		 10036
(Zip)		 4. If Amendment, Date of Original Filed (Month/Day/Year) Line) 6. Individual or Joint/Group Filing (Check Applicable
Form filed by One Reporting Person
Form filed by More than One Reporting
Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction
Date
(Month/Day/Year)		 2A. Deemed
Execution Date,
if any
(Month/Day/Year)		 3.
Transaction
Code (Instr.
8)		 4. Securities Acquired (A) or
Disposed Of (D) (Instr. 3, 4 and 5)		 5. Amount of
Securities
Beneficially
Owned Following
Reported		 6. Ownership
Form: Direct
(D) or Indirect
(I) (Instr. 4)		 7. Nature of
Indirect
Beneficial
Ownership
(Instr. 4)
Code V Amount (A) or
(D)		 Price Transaction(s)
(Instr. 3 and 4)
Common Stock 12/31/2025 A 97,328(1) (1)
\$0		 930,495 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of
Derivative
Security
(Instr. 3)		 2.
Conversion
or Exercise
Price of
Derivative
Security		 3. Transaction
Date
(Month/Day/Year)		 3A. Deemed
Execution Date,
if any
(Month/Day/Year)		 4.
Transaction
Code (Instr.
8)		 5. Number
of
Derivative
Securities
Acquired
(A) or
Disposed
of (D) (Instr.
3, 4 and 5)		 6. Date Exercisable and
Expiration Date
(Month/Day/Year)		 7. Title and Amount
of Securities
Underlying
Derivative Security
(Instr. 3 and 4)		 8. Price of
Derivative
Security
(Instr. 5)		 9. Number of
derivative
Securities
Beneficially
Owned
Following
Reported
Transaction(s)
(Instr. 4)		 10.
Ownership
Form:
Direct (D)
or Indirect
(I) (Instr. 4)		 11. Nature
of Indirect
Beneficial
Ownership
(Instr. 4)
Code V (A) (D) Date
Exercisable		 Expiration
Date		 Amount
or
Number
of
Shares
Performance
Stock Units		 (3) 12/31/2025 A 19,000 (3) (3) Common
Stock		 19,000 \$0 19,000 D

Explanation of Responses:

    1. Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value \$0.012 per share ("Common Stock"), of the Issuer.
    1. Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.
    1. Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria.

/s/ Joshua Hexter 01/05/2026

(2) 1,045,495 D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

  • * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
  • ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Common Stock 12/31/2025 A 115,000(2) A \$0

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Washington, D.C. 20549

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Instruction 10.
1. Name and Address of Reporting Person*
KIDRON NADAV		 2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director		 10% Owner
(Last)
(First)		 (Middle) ORMP ] Officer (give title
below)		 below) Other (specify
1185 AVENUE OF THE AMERICAS,
THIRD FLOOR		 12/31/2025 3. Date of Earliest Transaction (Month/Day/Year) President and CEO
(Street)
NEW YORK
NY
(City)
(State)		 10036
(Zip)		 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable
Line)
Form filed by One Reporting Person
Form filed by More than One Reporting
Person
1. Title of Security (Instr. 3) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
2. Transaction
2A. Deemed
Date
Execution Date,
(Month/Day/Year)
if any
(Month/Day/Year)		 3.
Transaction
Code (Instr.
8)		 4. Securities Acquired (A) or
Disposed Of (D) (Instr. 3, 4 and 5)		 5. Amount of
Securities
Beneficially
Owned Following		 6. Ownership
Form: Direct
(D) or Indirect
(I) (Instr. 4)		 7. Nature of
Indirect
Beneficial
Ownership
Code V Amount (A) or
(D)		 Price Reported
Transaction(s)
(Instr. 3 and 4)		 (Instr. 4)
Common Stock 12/31/2025 A 232,640(1) A (1)
\$0		 2,919,238 D
Common Stock 12/31/2025 A 327,000(2) A (2)
\$0		 3,246,238 D
Common Stock 126,000 I By wholly
owned
corporation
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of
2.
Derivative
Conversion
Security
or Exercise
(Instr. 3)
Price of
Derivative
Security		 3. Transaction
Date
(Month/Day/Year)		 3A. Deemed
Execution Date,
if any
(Month/Day/Year)		 4.
8)		 5. Number of
Transaction
Derivative
Code (Instr.
Securities
Acquired (A)
or Disposed
of (D) (Instr.
3, 4 and 5)		 Expiration Date
(Month/Day/Year)		 6. Date Exercisable and of Securities
Underlying
Derivative Security
(Instr. 3 and 4)		 7. Title and Amount 8. Price of
Derivative
derivative
Security
Securities
(Instr. 5)
Owned
Following
Reported		 9. Number of
Beneficially
Transaction(s)		 10.
Ownership
Form:
Direct (D)
or Indirect
(I) (Instr. 4)		 11. Nature
of Indirect
Beneficial
Ownership
(Instr. 4)
Date
Expiration
Code V
(A)
(D)
Exercisable
Date
Title		 Amount
or
Number
of Shares		 (Instr. 4)
Performance
(3)
Stock Units		 12/31/2025 A 109,000 (3) (3) Common
Stock		 109,000 \$0 109,000 D

Explanation of Responses:

    1. Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value \$0.012 per share ("Common Stock"), of the Issuer.
    1. Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.
    1. Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria.

/s/ Nadav Kidron 01/05/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

  • * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
  • ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

defense conditions of Rule 10b5-
1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Shapiro Benjamin		 2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC.
[
ORMP ]		 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director		 10% Owner
(Last) (First)
(Middle)
1185 AVENUE OF THE AMERICAS		 12/31/2025 3. Date of Earliest Transaction (Month/Day/Year) Officer (give title
below)
below)		 Other (specify
(Street)
NEW YORK
NY
10036		 4. If Amendment, Date of Original Filed (Month/Day/Year) Line) 6. Individual or Joint/Group Filing (Check Applicable
Form filed by One Reporting Person
Form filed by More than One Reporting
Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
2. Transaction
1. Title of Security (Instr. 3)
Date
(Month/Day/Year)		 2A. Deemed
Execution Date,
if any
(Month/Day/Year)		 3.
Transaction
Code (Instr.
8)		 4. Securities Acquired (A) or
Disposed Of (D) (Instr. 3, 4 and
5)		 Securities
Beneficially
Reported		 5. Amount of
Owned Following		 6. Ownership
Form: Direct
(D) or Indirect
(I) (Instr. 4)		 7. Nature
of Indirect
Beneficial
Ownership
(Instr. 4)
Code V Amount (D) (A) or Price Transaction(s)
(Instr. 3 and 4)
Common Stock 12/31/2025 A 30,000(1) A (1) 119,720 D
Common Stock
12/31/2025		 A 3,500(2) A (2) 123,220 D
Common Stock 1,900,000 I By
trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of
Derivative
Security
(Instr. 3)		 2.
Conversion
or Exercise
Price of
Derivative
Security		 3. Transaction
Date
(Month/Day/Year)		 3A. Deemed
if any		 Execution Date,
(Month/Day/Year)		 4.
Transaction
Code (Instr.
8)		 5. Number
of
Derivative
Securities
Acquired
(A) or
Disposed
of (D)
(Instr. 3, 4
and 5)		 6. Date Exercisable and
Expiration Date
(Month/Day/Year)		 7. Title and
Amount of
Securities
Underlying
Derivative
Security (Instr.
3 and 4)
Amount		 8. Price of
Derivative
Security
(Instr. 5)		 9. Number of
derivative
Securities
Beneficially
Owned
Following
Reported
Transaction(s)
(Instr. 4)		 10. Ownership
Form:
Direct (D)
or Indirect
(I) (Instr. 4)		 11. Nature
of Indirect
Beneficial
Ownership
(Instr. 4)
Code V (A) (D) Date
Exercisable		 Expiration
Date		 Title or
Number
of
Shares

Explanation of Responses:

    1. Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value \$0.012 per share ("Common Stock"), of the Issuer.
    1. Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.
    1. These shares of Common Stock are held by a trust of which the reporting person is a trustee and beneficiary.

/s/ Benjamin Shapiro 01/05/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

  • * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
  • ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

More from Oramed Pharmaceuticals Inc.

Regulatory Filings 2026
Jan 7
Regulatory Filings 2026
Jan 7
Regulatory Filings 2026
Jan 6
Regulatory Filings 2025
Dec 31
Regulatory Filings 2025
Dec 31
Regulatory Filings 2025
Nov 18
Foreign Filer Report 2025
Nov 18
Regulatory Filings 2025
Nov 18
Foreign Filer Report 2025
Nov 18
Regulatory Filings 2025
Nov 17
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.